Explain Entecavir
Entecavir (Baraclude) taken orally once a day as monotherapy appears to be superior to lamivudine for patients with chronic HBV infection, but susceptibility to entecavir may be reduced in patients refractory to lamivudine. How it compares with adefovir remains to be established, but HBV isolates from lamivudine-refractory patients failing entecavir therapy have remained susceptible to adefovir in vitro.